Usage and indications:
Levocarnine is indicated for:
A diagnosis of primary carnitine deficiency requires that serum, red cell and/or tissue carnitine level is below normal and that the patient does not have a primary defect in fatty acid or organic acid oxidation. In some patients, particularly those presenting with cardiomyopathy, carnitine supplementation rapidly alleviated signs and symptoms. Treatment should include, in addition to carnitine, supportive and other therapy as indicated by the condition of the patient.
Dosage and administration:
The recommended oral dose for:
Adults: is 990mg two or three times a day, depending on the clinical response.
Infants and children: is between 50 and 100mg/kg/day in divided doses, dosage should begin at 50mg/kg/day, and be increased slowly to a maximum of 3g/day.
The exact dosage will depend on patient condition and clinical response.
Clinical response should include periodic blood chemistries, vital signs, plasma carnitine concentrations and overall clinical condition.
Transient nausea, vomiting, abdominal cramps and diarrhea have been reported during the long-term administration.
Gastrointestinal adverse reactions might be avoided by a slow consumption of the solution or by a greater dilution.
It has been noticed only in uremic patients.
Seizures have been reported to occur in patients with or without pre-existing seizure activity.
In patients with pre-existing seizure activity, an increase in seizure frequency and/or severity has been reported.
Warnings and precautions:
The safety and efficacy of oral levocarnitine has not been evaluated in patients with renal insufficiency. Chronic administration of high doses of oral levocarnitine in patients with severely compromised renal function or in ESRD patients on dialysis may result in accumulation of the potentially toxic metabolites, trimethylamine (TMA) and trimethylamine-N-oxide (TMAO), since these metabolites are normally excreted in the urine.
Pack: Carton box containing (AL/PVC) strip of 10 tablets.